Ascensia partners with Senseonics on implantable CGMs
By HME News Staff
Updated Tue August 11, 2020
BASEL, Switzerland - PHC Holdings Corporation and Ascensia Diabetes Care have announced a strategic partnership with Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. As part of the agreement, Ascensia will serve as the exclusive global distribution partner for Senseonics' CGM systems, including Eversense, Eversense XL and future generation products in development, such as the 365-day implantable sensor. In the U.S., Ascensia will initiate marketing and sales activities of the Eversense product in the coming months, in collaboration with Senseonics, and will take over full responsibility in the first quarter of 2021. “We are thrilled to be entering into this partnership with Senseonics and strongly believe in the value of the Eversense technology,” said Robert Schumm, president of Ascensia Diabetes Care and Diabetes Management Domain Head. “This partnership is the next step in building a world-class diabetes care franchise for Ascensia, as we look to expand our business beyond blood glucose monitoring.” PHC is the parent company of Acensia.
Comments